Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Yong Li's publication output changed over time?
ScholarIQpublication output · 2006–2019
Output grew0% over the shown period — from 1 works in 2006 to 1 in 2019.
1
1
2
3
1
2
1
1
20062007200920102012201320162019
What are the most-cited papers on Yong Li?
ScholarIQmost cited works
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Arun Sreekumar, Laila Poisson, Thekkelnaycke M. Rajendiran, Amjad Khan, Qi Cao, Jindan Yu, Bharathi Laxman, Rohit Mehra, Robert J. Lonigro, Yong Li, Mukesh K. Nyati, Aarif Ahsan, Shanker Kalyana‐Sundaram, Bo Han, Xuhong Cao, Jaeman Byun, Gilbert S. Omenn, Debashis Ghosh, Subramaniam Pennathur, Danny C. Alexander, Alvin Berger, Jeffrey R. Shuster, John T. Wei, Sooryanarayana Varambally, Chris Beecher, Arul M. Chinnaiyan
Nature. 20092,260 CitationsOPEN ACCESS
An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression
Jindan Yu, Jianjun Yu, Ram S. Mani, Qi Cao, J. Chad Brenner, Xuhong Cao, Xiaoju Wang, Longtao Wu, James Li, Ming Hu, Yusong Gong, Hong Cheng, Bharathi Laxman, Adaikkalam Vellaichamy, Sunita Shankar, Yong Li, Saravana M. Dhanasekaran, Roger E. Morey, Terrence R. Barrette, Robert J. Lonigro, Scott A. Tomlins, Sooryanarayana Varambally, Zhaohui Qin, Arul M. Chinnaiyan
S25671836. 2010860 CitationsOPEN ACCESS
Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1
Chi Lam Au Yeung, Ngai-Na Co, Tetsushi Tsuruga, Tsz-Lun Yeung, Suet‐Ying Kwan, Cecilia S. Leung, Yong Li, Edward S. Lu, Kenny Kwan, Kwong‐Kwok Wong, Rosemarie Schmandt, Karen H. Lu, Samuel C. Mok
Nature Communications. 2016793 CitationsOPEN ACCESS
MicroRNA-155 Functions as an OncomiR in Breast Cancer by Targeting the <i>Suppressor of Cytokine Signaling 1</i> Gene
Shuai Jiang, Hong-Wei Zhang, Ming-Hua Lu, Xiao-Hong He, Yong Li, Hua Gu, Mo‐Fang Liu, En-Duo Wang
Cancer Research. 2010676 CitationsOPEN ACCESS
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N. Moore, Angeles Alvarez Secord, Melissa A. Geller, David S. Miller, Noelle Cloven, Gini F. Fleming, Andrea E. Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M. Oza, Mihaela Cristea, Jonathan S. Berek, John K. Chan, B.J. Rimel, Daniela Matei, Yong Li, Kaiming Sun, Katarina Luptakova, Ursula A. Matulonis, Bradley J. Monk
The Lancet Oncology. 2019540 Citations
Related on ScholarIQ
Hengshui University
Institution
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Paper
An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression
Paper
Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1
Paper
MicroRNA-155 Functions as an OncomiR in Breast Cancer by Targeting the <i>Suppressor of Cytokine Signaling 1</i> Gene
Paper
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Paper